Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Medtronic
Mallinckrodt
AstraZeneca
Merck
McKinsey
McKesson

Last Updated: December 3, 2022

Details for Patent: 8,680,103


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Which drugs does patent 8,680,103 protect, and when does it expire?

Patent 8,680,103 protects SPRYCEL and is included in one NDA.

Protection for SPRYCEL has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has forty-seven patent family members in twenty-nine countries.

Summary for Patent: 8,680,103
Title:Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
Abstract: The invention relates to a pharmaceutical composition of a crystalline monohydrate of the compound of formula (IV) ##STR00001## wherein the crystalline monohydrate is characterized by certain unit cell parameters.
Inventor(s): Lajeunesse; Jean (Candiac, CA), DiMarco; John D. (East Brunswick, NJ), Galella; Michael (Kendall Park, NJ), Chidambaram; Ramakrishnan (Santa Clara, CA)
Assignee: Bristol-Myers Squibb Company (Princeton, NJ)
Application Number:13/562,399
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,680,103
Patent Claim Types:
see list of patent claims
Composition; Compound;

Drugs Protected by US Patent 8,680,103

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Bristol Myers Squibb SPRYCEL dasatinib TABLET;ORAL 021986-001 Jun 28, 2006 RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Bristol Myers Squibb SPRYCEL dasatinib TABLET;ORAL 021986-002 Jun 28, 2006 RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Bristol Myers Squibb SPRYCEL dasatinib TABLET;ORAL 021986-003 Jun 28, 2006 RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Bristol Myers Squibb SPRYCEL dasatinib TABLET;ORAL 021986-005 Oct 28, 2010 RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Mallinckrodt
Express Scripts
Moodys
Colorcon
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.